Stoke Therapeutics, Inc.
US ˙ NasdaqGS ˙ US86150R1077

SecuritySTOK / Stoke Therapeutics, Inc.
InstitutionQUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series
Latest Disclosed Ownership71,005 shares
Latest Disclosed Value $ 805,906
QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series reports 15.70% increase in ownership of STOK / Stoke Therapeutics, Inc.

On August 26, 2025 - QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series filed a NPORT-P form disclosing ownership of 71,005 shares of Stoke Therapeutics, Inc. (US:STOK) valued at $805,907 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 28, 2025 disclosing 61,368 shares of Stoke Therapeutics, Inc.. This represents a change in shares of 15.70% during the quarter. The current value of the position is $2,130,860 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2025-08-26 2025-06-30 NP Stoke Therapeutics EC US86150R1077 71,005 9,637 15.70 806 97.30 0.0181
2025-05-28 2025-03-31 NP Stoke Therapeutics EC US86150R1077 61,368 0 0.00 408 -39.64 0.0098
2025-02-25 2024-12-31 NP Stoke Therapeutics EC US86150R1077 61,368 -9,542 -13.46 677 -22.39 0.0148
2024-11-26 2024-09-30 NP Stoke Therapeutics EC US86150R1077 70,910 18,949 36.47 871 24.25 0.0165
2024-08-26 2024-06-30 NP Stoke Therapeutics EC US86150R1077 51,961 4,066 8.49 702 8.51 0.0143
2024-05-28 2024-03-31 NP Stoke Therapeutics EC US86150R1077 47,895 0 0.00 647 157.37 0.0135
2024-02-26 2023-12-31 NP Stoke Therapeutics EC US86150R1077 47,895 0 0.00 252 33.51 0.0054
2023-11-28 2023-09-30 NP Stoke Therapeutics EC US86150R1077 47,895 0 0.00 189 -63.06 0.0049
2023-08-25 2023-06-30 NP Stoke Therapeutics EC US86150R1077 47,895 13,366 38.71 509 77.35 0.0121
2023-05-26 2023-03-31 NP Stoke Therapeutics EC US86150R1077 34,529 0 0.00 288 -9.75 0.0077
2023-02-24 2022-12-31 NP Stoke Therapeutics EC US86150R1077 34,529 0 0.00 319 -28.22 0.0088
2022-11-25 2022-09-30 NP Stoke Therapeutics EC US86150R1077 34,529 4,574 15.27 443 12.15 0.0127
2022-08-25 2022-06-30 NP Stoke Therapeutics EC US86150R1077 29,955 0 0.00 396 -37.30 0.0109
2022-05-26 2022-03-31 NP Stoke Therapeutics EC US86150R1077 29,955 1,341 4.69 631 -8.16 0.0147
2022-02-25 2021-12-31 NP Stoke Therapeutics EC US86150R1077 28,614 0 0.00 686 -5.64 0.0149
2021-11-24 2021-09-30 NP Stoke Therapeutics EC US86150R1077 28,614 0 0.00 728 -24.51 0.0160
2021-08-26 2021-06-30 NP Stoke Therapeutics EC US86150R1077 28,614 8,263 40.60 963 21.90 0.0207
2021-05-27 2021-03-31 NP Stoke Therapeutics EC US86150R1077 20,351 1,551 8.25 790 -32.13 0.0179
2021-02-25 2020-12-31 NP Stoke Therapeutics EC US86150R1077 18,800 -2,346 -11.09 1,164 64.41 0.0298
2020-11-25 2020-09-30 NP Stoke Therapeutics EC US86150R1077 21,146 0 0.00 708 40.76 0.0227
2020-08-27 2020-06-30 NP Stoke Therapeutics EC US86150R1077 21,146 -6,387 -23.20 504 -20.16 0.0165
2020-06-01 2020-03-31 NP Stoke Therapeutics EC US86150R1077 27,533 13,576 97.27 631 59.49 0.0258
2020-02-27 2019-12-31 NP Stoke Therapeutics EC 86150R107 13,957 0 0.00 395 32.11 0.0119
2019-11-27 2019-09-30 NP Stoke Therapeutics EC US86150R1077 13,957 13,957 300 0.0099
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.